Ribometrix, headquartered in Durham, North Carolina, is a biotechnology company leveraging world-leading expertise in three-dimensional structural analysis of RNA as the foundation of its proprietary drug discovery platform. This platform enables the identification of novel small molecules that modulate the function of RNA and proteins associated with human disease. Ribometrix’ value creation strategy is built around developing an internal pipeline of drug candidates and partnerships with the leading biopharmaceutical companies. Ribometrix is backed by a syndicate of blue-chip venture investors. 

Information Technology

Ribometrix

Mike Solomon

Barry Wilson

Sarah Thompson

Katie Warner

Murty Changalvala

Ramamurty Changalvala

Kevin Weeks

Orshi Kocsis

Jessica Sorrentino

Barclay Phillips

The Research and Development team at Ribometrix focuses on harnessing advanced structural analysis of RNA to drive the discovery of innovative drug candidates. This multidisciplinary group, consisting of experts in medicinal chemistry, RNA biology, and translational medicine, collaborates to translate scientific insights into actionable therapeutic strategies, advancing the company’s internal drug pipeline and fostering partnerships with leading biopharmaceutical firms. Their goal is to develop small molecules that effectively modulate RNA and protein functions linked to human diseases.

Research and Development

Leadership Team

Finance and Accounting

Research and Development

About

Team members

Other teams at Ribometrix

Leadership Team

Finance and Accounting